阿波利波蛋白E调节了阿尔茨海默病的非APOE多基因风险评分和临床前认知功能的衰老之间的关联
Yuexuan Xu1, Zhongxuan Sun2, Erin Jonaitis3,4
1Department of Population Health Science, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|October 20, 2023
概括
APOE ε4等位基因与多基因风险评分 (PRS) 相互作用,影响认知衰退,特别是在70岁左右. 具有APOE ε4和高PRS的个体最容易受到阿尔茨海默病遗传风险的影响.
科学领域:
- 神经遗传学 神经遗传学
- 阿尔茨海默氏症疾病研究研究
- 认知老龄化 认知老龄化
背景情况:
- 阿尔茨海默病 (AD) 的临床前认知衰退有所不同,这表明除了APOE ε4之外的遗传因素会影响疾病的进展.
- 多基因风险评分 (PRS) 聚合了常见遗传变异的影响,可能与已知的风险等位基因相互作用,如APOE ε4.4.
研究的目的:
- 研究多基因风险评分 (PRS),APOE ε4等位基因和年龄对临床前认知功能的相互作用.
- 确定PRS是否会改变APOE ε4状态与纵向认知衰退之间的关联.
主要方法:
- 分析了来自威斯康星州阿尔茨海默氏症预防登记处的1190人长度认知数据.
- 使用线性混合效应模型测试了PRS × APOE ε4 ×年龄相互作用的认知指标,并根据家族相关性进行调整.
- 结果在一个独立的基于人口的队列中得到了验证.
主要成果:
- 对于立即学习,延迟回忆和临床前阿尔茨海默氏症认知复合3分数,观察到统计学意义上的PRS × APOE ε4 × 年龄相互作用.
- 与PRS相关的认知表现差异在70岁左右出现,APOE ε4载体的不良影响更为明显.
- 观察到的相互作用在单独的队列中被复制,证实了研究结果的稳定性.
结论:
- APOE ε4等位基因显著改变了多基因风险得分与纵向认知衰退之间的关联.
- 携带APOE ε4等位基因并具有高PRS的个体有较高的认知障碍风险,特别是在70岁左右.
- 这些发现突显了AD病变发生过程中遗传因素的复杂相互作用,并确定了针对性干预的高风险子组.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
相关概念视频
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
